LabinazMZidarJPStackRS, et al. Biodegradable stents: the future of interventional cardiology?J Interv Cardiol. 1995;8:395–405.
2.
TamaiHIgakiKKyoE, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102:399–404.
3.
BosiersMPeetersPD’ArchambeauO, et al; AMS INSIGHT Investigators. AMS INSIGHT—absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol. 2009;32:424–435.
4.
KumSIpemaJChun-yinDH, et al. Early and midterm experience with the Absorb everolimus-eluting bioresorbable vascular scaffold in Asian patients with chronic limb-threatening ischemia: one-year clinical and imaging outcomes from the DISAPEAR Registry. J Endovasc Ther. 2020;27(4:616–622.
5.
VarcoeRLSchoutenOThomasSD, et al. Experience with the Absorb everolimus-eluting bioresorbable vascular scaffold in arteries below the knee. JACC Cardiovasc Interv. 2016;9:1721–1728.
6.
VarcoeRLThomasSDLennoxAF. Three-year results of the Absorb everolimus-eluting bioresorbable vascular scaffold in infrapopliteal arteries. J Endovasc Ther. 2018;25:694–701.
7.
DiaAVenturiniJMKalathiyaR, et al. Single arm retrospective study of bioresorbable vascular scaffolds to treat patients with severe infrapopliteal arterial disease. Catheter Cardiovasc Interv. 2019;94:1028–1033.
8.
LammerJBosiersMDelooseK, et al. Bioresorbable everolimus-eluting vascular scaffold for patients with peripheral artery disease (ESPRIT I): 2-year clinical and imaging results. JACC Cardiovasc Interv. 2016;9:1178–1187.
9.
WernerMMicariACioppaA, et al. Evaluation of the biodegradable peripheral Igaki-Tamai stent in the treatment of de novo lesions in the superficial femoral artery: the GAIA study. JACC Cardiovasc Interv. 2014;7:305–312.
10.
WernerMSchmidtAScheinertS, et al. Evaluation of the biodegradable Igaki-Tamai scaffold after drug-eluting balloon treatment of de novo superficial femoral artery lesions: the GAIA-DEB study. J Endovasc Ther. 2016;23:92–97.
11.
LinniKUgurluogluAHitzlW, et al. Bioabsorbable stent implantation vs. common femoral artery endarterectomy: early results of a randomized trial. J Endovasc Ther. 2014;21:493–502.
12.
SilingardiRLauricellaACoppiG, et al. Midterm results of endovascular treatment of superficial femoral artery disease with biodegradable stents: single-center experience. J Vasc Interv Radiol. 2015;26:374–381.
13.
MuketeBNvan der HeijdenLCTandjungK, et al. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: a systematic review and meta-analysis of studies. Int J Cardiol. 2016;221:1087–1094.
14.
KangSHGogasBDJeonKH, et al. Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials. EuroIntervention. 2018;13:1904–1913.
15.
TenekeciogluESerruysPWOnumaY, et al. Randomized comparison of Absorb bioresorbable vascular scaffold and Mirage microfiber sirolimus-eluting scaffold using multimodality imaging. JACC Cardiovasc Interv. 2017;10:1115–1130.
16.
HehrleinCSchorchBKressN, et al. Zn-alloy provides a novel platform for mechanically stable bioresorbable vascular stents. PLoS One. 2019;14:e0209111.
17.
Gomez-LaraJRaduMBrugalettaS, et al. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. JACC Cardiovasc Interv. 2011;4:992–1001.
18.
Biondi-ZoccaiGRomagnoliEFratiG, et al. Commentary: Why metallic stents remain the worst type of endovascular device, except for all the others. J Endovasc Ther. 2018;25:702–705.
